Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Published: Mar 2024 Pages: 155 SKU: IRTNTR77810

Chronic Lymphocytic Leukemia (CLL) Therapeutics Market Forecast 2024-2028

The Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market size is forecast to increase by USD 2.92 billion, at a CAGR of 8.82% between 2023 and 2028

There has been an increase in research grants for different blood cancers across the globe. In addition, for the treatment of blood cancers which include chronic lymphocytic leukemia, there are various approved therapies, and the pipeline witnesses the presence of novel drugs from several vendors, which are undergoing clinical trials. Moreover, there are some small institutions and CROs working on the development of novel medications for the treatment of rare conditions. For instance, the Leukemia and Lymphoma Society is another organization that focuses on funding for the development of blood cancer therapeutics, including for chronic lymphocytic leukemia. Hence, such factors are positively impacting the market.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Route Of Administration, Therapy, and Geography Analysis

The market is a critical sector within the pharmaceutical markets, focusing on addressing the complexities of this disease's epidemiology, symptoms, diagnosis, and disease management. Innovative approaches such as clinical trial mapping are shaping the landscape of the CLL therapeutics market, targeting B-lymphocytes in peripheral blood and other affected areas like Bone marrow, Lymph nodes, and Tissues. While distinct from CML (Chronic Myeloid Leukemia), ongoing cancer research fuels the development of new therapies, including chemotherapy, regenerative medicine, and stem-cell transplant, paving the way for personalized medicine advancements supported by organizations like the Leukemia & Lymphoma Society and facilities like the Centre for Commercialization of Regenerative Medicine (CCRM).

Route Of Administration Analysis

The parenteral segment is estimated to witness significant growth during the forecast period. The parenteral route of administration segment is a common and well-established method for delivering chronic lymphocytic leukemia biologics. In addition, this approach involves introducing therapeutic agents directly into the bloodstream using various methods, such as intravenous (IV), subcutaneous (SC), or intramuscular (IM) injections. Furthermore, parenteral biology often consists of large, complex molecules that necessitate their precise delivery to ensure effective treatment.

Get a glance at the market contribution of various segments Download PDF Sample

The parenteral segment was the largest segment and was valued at USD 3.40 billion in 2018. Moreover, intravenous injections are a widely used method for administering therapeutics for chronic lymphocytic leukemia directly into the veins of patients. In addition, this enables the rapid and complete systemic distribution of the therapeutic agents throughout the body. Furthermore, the intravenous route is particularly suitable for biologics that require immediate and extensive distribution to reach cancer cells located in different organs or tissues in the body. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.

Therapy Analysis

Chemotherapy is a main type of chronic lymphocytic leukemia therapeutics, which leverages one or more anticancer drugs as part of the standard treatment. In addition, chemotherapy can be a curative treatment, which involves a combination of drugs at times. Moreover, even if chemotherapy cannot cure cancer completely, it can at least prolong the patient's life or reduce the symptoms of cancer (palliative chemotherapy). Furthermore, chemotherapy is one of the major treatment options for chronic lymphocytic leukemia. In addition, it kills fast-growing cells such as leukemia cells. Hence, such factors are fuelling the growth of this segment which in turn drives the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The growth of the chronic lymphocytic leukemia market in North America is primarily driven by the sales of approved drugs for the treatment of chronic lymphocytic leukemia and the increasing prevalence of various blood cancer types, including leukemia. In addition, the presence of key vendors in the region, which include AbbVie., Bristol Myers Squibb, and Pfizer, will positively impact the chronic lymphocytic leukemia market in the region. In addition, chronic lymphocytic leukemia is curable if diagnosed and treated in the early stages. Furthermore, chronic lymphocytic leukemia is mostly diagnosed in people aged 60 years and above. Hence, such factors are driving the market in North America during the forecast period.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers chronic lymphocytic leukemia therapeutics products such as VENCLYXTO used in combination with obinutuzumab to treat adults with previously untreated CLL and VENCLEXTA used to treat adults with CLL or small lymphocytic lymphoma.

Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., R2T BIOPHARMA INC, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is driven by advancements in cancer research, leading to the development of new therapies and personalized medicine approaches. Key trends include the rise of clinical trial mapping for targeted treatments and the focus on regenerative medicine like stem-cell transplants. Challenges include the complexity of diagnosis due to disease heterogeneity, the need for effective disease management, and navigating chemotherapy options. Organizations like the Leukemia & Lymphoma Society and research facilities such as the Centre for Commercialization of Regenerative Medicine (CCRM) play vital roles in addressing these challenges. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key chronic lymphocytic leukemia therapeutics market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Significant  Trends

Special drug designations for chronic lymphocytic leukemia therapeutics are an emerging trend in the market. Drugs that cure chronic lymphocytic leukemia and therapeutic candidates that are presently under development for the treatment of the condition have been awarded special drug designations by drug safety and regulatory bodies, considering their proven efficacy. In addition, many such drugs have received designations such as the breakthrough drug designation and the orphan drug designation (ODD) from regulatory bodies such as the US Food and Drug Administration (FDA) in the US and the European Medicines Agency (EMA).

Moreover, some of the key drug designations include breakthrough, fast track, and orphan drugs. In addition, these designations help enhance research and enable key drugs to reach the market at the earliest. Furthermore, companies that have received the orphan drug designation for their drugs also get certain benefits. Hence, such factors are driving the market during the forecast period.

Major  Challenges

The adverse effects of chemotherapy drugs are a major challenge hindering the market. Even though the treatment landscape for leukemia, such as chronic lymphocytic leukaemia, is developing rapidly, the number of treatment options for chronic lymphocytic leukemia is limited as it is a rare disease. In addition, the treatment landscape of chronic lymphocytic leukemia is mainly dominated by chemotherapy.

Moreover, chemotherapy drugs demonstrate a range of adverse side effects, such as fatigue, muscle cramps, nausea, vomiting, and diarrhea. In addition, chemotherapy functions by focusing on destroying living cells. Furthermore, cells that are developing and dividing as a regular part of the cell cycle are known as active cells. Hence, such factors are hindering the market during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Route Of Administration Outlook
    • Parenteral
    • Oral
  • Therapy Outlook
    • Chemotherapy
    • Targeted
    • Others
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • APAC
      • China
      • India
    • Rest of the World (ROW)
      • Australia
      • Argentina
      • Brazil

Market Analyst Overview

The market is driven by advancements in novel and innovative drugs and immunotherapies, providing targeted treatment options for patients. With an aging geriatric population, there's a growing need for effective targeted drugs and FDA-approved immunotherapy. Symptoms such as fever, infection, and pain prompt early diagnosis, particularly among males, females, and Asian populations. Drug therapy, including monoclonal antibody therapies and radiation therapy, aims to mitigate malignancy and reduce mortality rates. Emerging pipeline drugs and branded medications offer promising pharmacological treatments for CLL, including BTK inhibitors, PI3K inhibitors, and CAR-T and NK cell therapies targeting CD20 antigen and BCL-2 inhibitors.

Further, effective management through examination and splenectomy underscores the importance of targeted therapy in improving patient outcomes. The leukemia therapeutics market witnesses a surge in novel and innovative drugs targeting specific pathways, distinguishing them from acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML). Symptoms like weight loss and enlarged ribs often prompt diagnosis, with viruses implicated as potential causes. Targeted therapies and monoclonal antibody drugs offer tailored treatment options, while branded drugs and pipeline molecules continue to expand treatment possibilities. Monitoring blood cell counts is crucial for disease management, highlighting the importance of ongoing research into CLL therapeutics.

Market Scope

Report Coverage

Details

Page number

155

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 8.82%

Market Growth 2024-2028

USD 2.92 billion

Market structure

Concentrated

YoY growth 2023-2024(%)

7.54

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., R2T BIOPHARMA INC, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Market dynamics

Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the between 2023 and 2028
  • Precise estimation of the size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate predictions about upcoming market trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market growth and forecasting analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global chronic lymphocytic leukemia therapeutics market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global chronic lymphocytic leukemia therapeutics market 2018 - 2022 ($ billion)
    • 4.2 Route Of Administration Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Route Of Administration Segment 2018 - 2022 ($ billion)
    • 4.3 Therapy Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Therapy Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Route of Administration

    • 6.1 Market segments
      • Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
    • 6.2 Comparison by Route of Administration
      • Exhibit 32: Chart on Comparison by Route of Administration
      • Exhibit 33: Data Table on Comparison by Route of Administration
    • 6.3 Parenteral - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Parenteral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Parenteral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Parenteral - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Parenteral - Year-over-year growth 2023-2028 (%)
    • 6.4 Oral - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Oral - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Oral - Year-over-year growth 2023-2028 (%)
    • 6.5 Market opportunity by Route of Administration
      • Exhibit 42: Market opportunity by Route of Administration ($ billion)
      • Exhibit 43: Data Table on Market opportunity by Route of Administration ($ billion)

    7 Market Segmentation by Therapy

    • 7.1 Market segments
      • Exhibit 44: Chart on Therapy - Market share 2023-2028 (%)
      • Exhibit 45: Data Table on Therapy - Market share 2023-2028 (%)
    • 7.2 Comparison by Therapy
      • Exhibit 46: Chart on Comparison by Therapy
      • Exhibit 47: Data Table on Comparison by Therapy
    • 7.3 Chemotherapy - Market size and forecast 2023-2028
      • Exhibit 48: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 49: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 50: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%)
      • Exhibit 51: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%)
    • 7.4 Targeted - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Targeted - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Targeted - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Targeted - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Targeted - Year-over-year growth 2023-2028 (%)
    • 7.5 Others - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Therapy
      • Exhibit 60: Market opportunity by Therapy ($ billion)
      • Exhibit 61: Data Table on Market opportunity by Therapy ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 63: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 64: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 65: Chart on Geographic comparison
      • Exhibit 66: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 China - Market size and forecast 2023-2028
      • Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.10 Japan - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.11 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 103: Market opportunity by geography ($ billion)
      • Exhibit 104: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 105: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 107: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 108: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 109: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 110: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 111: AbbVie Inc. - Overview
              • Exhibit 112: AbbVie Inc. - Product / Service
              • Exhibit 113: AbbVie Inc. - Key news
              • Exhibit 114: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 115: Amgen Inc. - Overview
              • Exhibit 116: Amgen Inc. - Product / Service
              • Exhibit 117: Amgen Inc. - Key offerings
            • 12.5 AstraZeneca PLC
              • Exhibit 118: AstraZeneca PLC - Overview
              • Exhibit 119: AstraZeneca PLC - Product / Service
              • Exhibit 120: AstraZeneca PLC - Key news
              • Exhibit 121: AstraZeneca PLC - Key offerings
            • 12.6 Biogen Inc.
              • Exhibit 122: Biogen Inc. - Overview
              • Exhibit 123: Biogen Inc. - Product / Service
              • Exhibit 124: Biogen Inc. - Key news
              • Exhibit 125: Biogen Inc. - Key offerings
            • 12.7 Bristol-Myers Squibb Company
              • Exhibit 126: Bristol-Myers Squibb Company - Overview
              • Exhibit 127: Bristol-Myers Squibb Company - Product / Service
              • Exhibit 128: Bristol-Myers Squibb Company - Key news
              • Exhibit 129: Bristol-Myers Squibb Company - Key offerings
            • 12.8 F. Hoffmann La Roche Ltd.
              • Exhibit 130: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 131: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 132: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 133: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 134: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.9 Gilead Sciences Inc.
              • Exhibit 135: Gilead Sciences Inc. - Overview
              • Exhibit 136: Gilead Sciences Inc. - Product / Service
              • Exhibit 137: Gilead Sciences Inc. - Key news
              • Exhibit 138: Gilead Sciences Inc. - Key offerings
            • 12.10 GlaxoSmithKline Plc
              • Exhibit 139: GlaxoSmithKline Plc - Overview
              • Exhibit 140: GlaxoSmithKline Plc - Business segments
              • Exhibit 141: GlaxoSmithKline Plc - Key news
              • Exhibit 142: GlaxoSmithKline Plc - Key offerings
              • Exhibit 143: GlaxoSmithKline Plc - Segment focus
            • 12.11 Novartis AG
              • Exhibit 144: Novartis AG - Overview
              • Exhibit 145: Novartis AG - Business segments
              • Exhibit 146: Novartis AG - Key news
              • Exhibit 147: Novartis AG - Key offerings
              • Exhibit 148: Novartis AG - Segment focus
            • 12.12 Pfizer Inc.
              • Exhibit 149: Pfizer Inc. - Overview
              • Exhibit 150: Pfizer Inc. - Product / Service
              • Exhibit 151: Pfizer Inc. - Key news
              • Exhibit 152: Pfizer Inc. - Key offerings
            • 12.13 R2T BIOPHARMA INC
              • Exhibit 153: R2T BIOPHARMA INC - Overview
              • Exhibit 154: R2T BIOPHARMA INC - Product / Service
              • Exhibit 155: R2T BIOPHARMA INC - Key offerings
            • 12.14 Sanofi SA
              • Exhibit 156: Sanofi SA - Overview
              • Exhibit 157: Sanofi SA - Business segments
              • Exhibit 158: Sanofi SA - Key news
              • Exhibit 159: Sanofi SA - Key offerings
              • Exhibit 160: Sanofi SA - Segment focus
            • 12.15 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 161: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 162: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 163: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 164: Takeda Pharmaceutical Co. Ltd. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 165: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 166: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 167: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 169: Teva Pharmaceutical Industries Ltd. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 170: Inclusions checklist
                • Exhibit 171: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 172: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 173: Research methodology
                • Exhibit 174: Validation techniques employed for market sizing
                • Exhibit 175: Information sources
              • 13.5 List of abbreviations
                • Exhibit 176: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              chronic lymphocytic leukemia therapeutics market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis